Comparative Pharmacology
Head-to-head clinical analysis: FIRMAGON versus ZEGALOGUE AUTOINJECTOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FIRMAGON versus ZEGALOGUE AUTOINJECTOR.
FIRMAGON vs ZEGALOGUE (AUTOINJECTOR)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gonadotropin-releasing hormone (GnRH) receptor antagonist; competitively binds to GnRH receptors in the anterior pituitary, rapidly reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby suppressing testosterone production in males.
Zegalogue (dasiglucagon) is a glucagon analog that binds to glucagon receptors, activating adenylate cyclase and increasing cAMP levels, which promotes glycogenolysis and gluconeogenesis in the liver, thereby raising blood glucose levels.
For advanced prostate cancer: 120 mg subcutaneously as a loading dose (two 60 mg injections), then 80 mg subcutaneously once monthly (one 80 mg injection) starting 28 days after the loading dose.
0.25 mg intramuscularly (IM) as a single dose into the anterolateral thigh, repeated once after 15 minutes if necessary.
None Documented
None Documented
Terminal elimination half-life is approximately 63 days after subcutaneous administration in patients with prostate cancer, allowing for monthly dosing schedules.
50–65 minutes (terminal elimination half-life).
Primarily hepatobiliary; about 90% of the dose is eliminated in feces as unchanged drug, with less than 5% excreted renally as unchanged drug and metabolites.
Primarily hepatic metabolism followed by biliary and fecal excretion, with negligible renal elimination (<2%).
Category C
Category C
GnRH Antagonist
GnRH Antagonist